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Current clinical trials that evaluate human pluripotent stem cell (hPSC)-based therapies 
predominantly target treating macular degeneration of the eyes because the eye is an isolated 
tissue that is naturally weakly immunogenic. Here, we discuss current bioengineering 
approaches and biomaterial usage in combination with stem cell therapy for macular 
degeneration disease treatment. Retinal pigment epithelium (RPE) differentiated from hPSCs 
is typically used in most clinical trials for treating patients, whereas bone marrow 
mononuclear cells (BMNCs) or mesenchymal stem cells (MSCs) are intravitreally 
transplanted, undifferentiated, into patient eyes. We also discuss reported negative effects of 
stem cell therapy, such as patients becoming blind following transplantation of adipose-
derived stem cells, which are increasingly used by 'stem-cell clinics'. 
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